The susceptibility of adenovirus infection to the anti-cytomegalovirus drug, ganciclovir (DHPG)

Taylor, D.L.; Jeffries, D J; Taylor-Robinson, D.; Parkin, Jacqueline; Tyms, A. S.

doi:10.1111/j.1574-6968.1988.tb02753.x

Cited by 23 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…184 Ganciclovir, ribavirin, and vidarabine each have limited in vitro activity against AdV. [223][224][225] Case reports and small series have reported successful outcomes with each treatment, but it is impossible to determine whether these patients would have recovered without therapy. 226 Cidofovir (CDV), a cytosine nucleotide analogue that inhibits DNA polymerase, has the greatest in vitro activity against AdV 223,227,228 and is the preferred therapeutic agent.…”

Section: Prevention and Treatmentmentioning

confidence: 99%

Respiratory Viral Infections in Hematopoietic Stem Cell and Solid Organ Transplant Recipients

Weigt

Gregson

Deng

et al. 2011

Semin Respir Crit Care Med

100

View full text Add to dashboard Cite

Respiratory viral infections (RVIs) are common causes of mild illness in immunocompetent children and adults with rare occurrences of significant morbidity or mortality. Complications are more common in the very young, very old, and those with underlying lung diseases. However, RVIs are increasingly recognized as a cause of morbidity and mortality in recipients of hematopoietic stem cell transplants (HSCT) and solid organ transplants (SOTs). Diagnostic techniques for respiratory syncytial virus (RSV), parainfluenza, influenza, and adenovirus have been clinically available for decades, and these infections are known to cause serious disease in transplant recipients. Modern molecular technology has now made it possible to detect other RVIs including human metapneumovirus, coronavirus, and bocavirus, and the role of these viruses in causing serious disease in transplant recipients is still being worked out. This article reviews the current information regarding epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of these infections, as well as the aspects of clinical significance of RVIs unique to HSCT or SOT.

show abstract

Section: Prevention and Treatmentmentioning

confidence: 99%

Respiratory Viral Infections in Hematopoietic Stem Cell and Solid Organ Transplant Recipients

Weigt

Gregson

Deng

et al. 2011

Semin Respir Crit Care Med

100

View full text Add to dashboard Cite

show abstract

“…The Ad genome is not known to code for a kinase, and therefore, Ad might not be expected to be susceptible to GCV, yet GCV has been shown to inhibit the replication in vitro of many Ad types, including types with ocular tropism, with 50% effective concentrations (EC 50 ) ranging from 26 to 206 M, depending on the Ad type, the cell line used, and the method of evaluation (22)(23)(24)(25)(26)(27)(28)(29). Also, some reports noted that prophylactic treatment of transplant patients with GCV to prevent CMV infection seemed to decrease the incidence of Ad infections (30)(31)(32).…”

mentioning

confidence: 99%

Ganciclovir Inhibits Human Adenovirus Replication and Pathogenicity in Permissive Immunosuppressed Syrian Hamsters

Bai

Tollefson

Spencer

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Adenovirus infections of immunocompromised patients can develop into deadly multiorgan or systemic disease. The virus is especially threatening for pediatric allogeneic hematopoietic stem cell transplant recipients; according to some studies, 10% or more of these patients succumb to disease resulting from adenovirus infection. At present, there is no drug approved for the treatment or prevention of adenovirus infections. Compounds that are approved to treat other virus infections are used off-label to combat adenovirus, but only anecdotal evidence of the efficacy of these drugs exists. Ganciclovir, a drug approved for the treatment of herpesvirus infection, was previously reported to be effective against human adenoviruses in vitro. To model adenovirus infections in immunocompromised humans, we examined ganciclovir's efficacy in immunosuppressed Syrian hamsters intravenously infected with type 5 human adenovirus (Ad5). This animal model is permissive for Ad5 replication, and the animals develop symptoms similar to those seen in humans. We demonstrate that ganciclovir suppresses Ad5 replication in the liver of infected hamsters and that it mitigates the consequences of Ad5 infections in these animals when administered prophylactically or therapeutically. We show that ganciclovir inhibits Ad5 DNA synthesis and late gene expression. The mechanism of action for the drug is not clear; preliminary data suggest that it exerts its antiadenoviral effect by directly inhibiting the adenoviral DNA polymerase. While more extensive studies are required, we believe that ganciclovir is a promising drug candidate to treat adenovirus infections. Brincidofovir, a drug with proven activity against Ad5, was used as a positive control in the prophylactic experiment.

show abstract

“…La incidencia reportada por Wilhelmus et al, se calcula en 12-22 casos por 100,000 personas/año y se presentan un millón de episodios nuevos anualmente. La morbilidad ocular causada por la queratitis epitelial la coloca como la causa más común de ceguera por causas corneales 13 . La disminución en la capacidad visual se explica por la pérdida de la transparencia del tejido corneal, lo que imposibilita o distorsiona la llegada de rayos de luz a la retina.…”

Section: Discussionunclassified

Eficacia del ganciclovir tópico como alternativa terapéutica de la queratitis epitelial herpética

Alvarez-Guzman

Rodríguez-García²,

Torres-Gómez³

2014

Revista Mexicana de Oftalmología

View full text Add to dashboard Cite

ResumenObjetivo: Comparar el uso del ganciclovir con el del aciclovir, usados de forma tópica, para la curación de la queratitis epitelial herpética en menos de 7 días. Materiales y métodos: Se diseñó un ensayo clínico aleatorizado comparativo de pacientes con queratitis epitelial herpética del Centro de Oftalmología de la Fundación Santos y de la Garza Evia. Se establecieron 2 grupos de tratamiento: gel de ganciclovir 0.15% y ungüento de aciclovir 3%; aplicados 5 veces al día hasta el cierre de la dendrita y después 3 veces al día durante 3 días más. Se evaluó diariamente a los pacientes hasta el cierre de la úlcera y se aplicó un cuestionario de síntomas con una escala validada. Resultados: Se reclutaron 23 pacientes: 13 tratados con ganciclovir (56.5%) y 10 (43.4%) con aciclovir (p = 0.94); la edad promedio fue de 47.69 años (DE ± 18.6) para el primer grupo y de 56.8 años (DE ± 9.6) para el segundo (p = 0.17). El tamaño de la úlcera inicial fue similar en ambos grupos: 2.3 mm (± 1.85) en aciclovir y 3.0 mm (± 0.94) en ganciclovir. En el primer día la mediana del tamaño de la úlcera en aciclovir fue de 1.5 mm (RIC = 1.8) y en ganciclovir 1 mm (RIC = 1.9) (p = 0.257), lo cual no muestra una diferencia clínicamente significativa. Al día 7, la úlcera había cerrado a 0 mm (RIC = 0) en todos los casos de ganciclovir comparado con 1 mm promedio en el grupo de aciclovir (RIC = 1.7) (p = 0.000). Conclusiones: El ganciclovir demostró una curación de la queratitis epitelial en menos de 7 días, comparado con aciclovir.

show abstract

The susceptibility of adenovirus infection to the anti-cytomegalovirus drug, ganciclovir (DHPG)

Cited by 23 publications

References 13 publications

Respiratory Viral Infections in Hematopoietic Stem Cell and Solid Organ Transplant Recipients

Respiratory Viral Infections in Hematopoietic Stem Cell and Solid Organ Transplant Recipients

Ganciclovir Inhibits Human Adenovirus Replication and Pathogenicity in Permissive Immunosuppressed Syrian Hamsters

Eficacia del ganciclovir tópico como alternativa terapéutica de la queratitis epitelial herpética

Contact Info

Product

Resources

About